{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T22:04:09Z","timestamp":1711145049295},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,4,3]],"date-time":"2011-04-03T00:00:00Z","timestamp":1301788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00280-011-1603-2","type":"journal-article","created":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T22:46:58Z","timestamp":1301698018000},"page":"1377-1385","source":"Crossref","is-referenced-by-count":2,"title":["Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors"],"prefix":"10.1007","volume":"68","author":[{"given":"Patricia","family":"LoRusso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey I.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Jo","family":"Pilat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice","family":"Chemidlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Kollia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shariq","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Masson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,3]]},"reference":[{"issue":"19","key":"1603_CR1","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039\u20132049","journal-title":"N Engl J Med"},{"issue":"1","key":"1603_CR2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ, Bello CL, Theuer CP, George DJ, Rini BI (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24(1):16\u201324","journal-title":"J Clin Oncol"},{"issue":"24","key":"1603_CR3","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542\u20132550","journal-title":"N Engl J Med"},{"issue":"2","key":"1603_CR4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125\u2013134","journal-title":"N Engl J Med"},{"issue":"8","key":"1603_CR5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","volume":"8","author":"LM Ellis","year":"2008","unstructured":"Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8(8):579\u2013591","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1603_CR6","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"1","key":"1603_CR7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25\u201334","journal-title":"Lancet Oncol"},{"issue":"6","key":"1603_CR8","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdp533","volume":"21","author":"S Welch","year":"2010","unstructured":"Welch S, Spithoff K, Rumble RB, Maroun J (2010) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 21(6):1152\u20131162","journal-title":"Ann Oncol"},{"issue":"5","key":"1603_CR9","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2133.2009.09290.x","volume":"161","author":"WJ Lee","year":"2009","unstructured":"Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK (2009) Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 161(5):1045\u20131051","journal-title":"Br J Dermatol"},{"issue":"29","key":"1603_CR10","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1200\/JCO.2009.22.3875","volume":"27","author":"M Zangari","year":"2009","unstructured":"Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ (2009) Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 27(29):4865\u20134873","journal-title":"J Clin Oncol"},{"issue":"7","key":"1603_CR11","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1021\/jm051106d","volume":"49","author":"RS Bhide","year":"2006","unstructured":"Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, Barrish JC, Kim SH, Leavitt K, Mathur A, Leith L, Chao S, Wautlet B, Mortillo S, Jeyaseelan R, Kukral D, Hunt JT, Kamath A, Fura A, Vyas V, Marathe P, D\u2019Arienzo C, Derbin G, Fargnoli J (2006) Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49(7):2143\u20132146","journal-title":"J Med Chem"},{"key":"1603_CR12","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1158\/1078-0432.CCR-08-0509","volume":"14","author":"H Huynh","year":"2008","unstructured":"Huynh H, Ngo VC, Fargnoli J, Ayers M, Soreide O, Koong HN, Thng CH, Ong HS, Chow P, Pollock P, Byron S, Tran E (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14:6146\u20136153","journal-title":"Clin Cancer Res"},{"issue":"2","key":"1603_CR13","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1535-7163.MCT-09-0472","volume":"9","author":"RS Bhide","year":"2010","unstructured":"Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, Jeyaseelan R Sr, Mortillo S, Wautlet BS, Krishnan B, Kukral D, Malone H, Lewin AC, Henley BJ, Fargnoli J (2010) The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 9(2):369\u2013378","journal-title":"Mol Cancer Ther"},{"key":"1603_CR14","doi-asserted-by":"crossref","unstructured":"Jonker DJ, Rosen LS, Sawyer MB, de Braud F, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, Kollia G, Nuyten DS, Galbraith S (2010) A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Ann Oncol. doi: 10.1093\/annonc\/mdq599","DOI":"10.1093\/annonc\/mdq599"},{"key":"1603_CR15","unstructured":"Raoul J-L, Finn R, Kang YK, Park JW, Harris R, Coric V, Donica M, Walters I (2009) An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC) [abstract]. J Clin Oncol 27(15s). Abstract 4577"},{"issue":"24","key":"1603_CR16","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1158\/1078-0432.CCR-06-1249","volume":"12","author":"RC Kane","year":"2006","unstructured":"Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, Sridhara R, Garvey P, Justice R, Pazdur R (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12(24):7271\u20137278","journal-title":"Clin Cancer Res"},{"key":"1603_CR17","unstructured":"Nexavar (prescribing information) (2009) Bayer HealthCare Pharmaceuticals, Wayne"},{"key":"1603_CR18","unstructured":"Votrient (prescribing information) (2010) GlaxoSmithKline, Research Triangle Park"},{"issue":"18","key":"1603_CR19","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1200\/JCO.2008.20.9908","volume":"27","author":"AX Zhu","year":"2009","unstructured":"Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27(18):3027\u20133035","journal-title":"J Clin Oncol"},{"issue":"1","key":"1603_CR20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CAD.0b013e3283161012","volume":"20","author":"V Launay-Vacher","year":"2009","unstructured":"Launay-Vacher V, Deray G (2009) Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 20(1):81\u201382","journal-title":"Anticancer Drugs"},{"key":"1603_CR21","unstructured":"Sutent (prescribing information) (2010) Pfizer Inc., New York"},{"issue":"19","key":"1603_CR22","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300(19):2277\u20132285","journal-title":"JAMA"},{"issue":"3","key":"1603_CR23","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","volume":"49","author":"V Ranpura","year":"2010","unstructured":"Ranpura V, Hapani S, Chuang J, Wu S (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol 49(3):287\u2013297","journal-title":"Acta Oncol"},{"issue":"13","key":"1603_CR24","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","volume":"28","author":"TK Choueiri","year":"2010","unstructured":"Choueiri TK, Schutz FA, Je Y, Rosenberg JE, Bellmunt J (2010) Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 28(13):2280\u20132285","journal-title":"J Clin Oncol"},{"key":"1603_CR25","doi-asserted-by":"crossref","unstructured":"Garrett C, Siu L, El-Khoueiry A, Buter J, Rocha-Lima C, Marshall J, Mokliatchouk O, Velasquez L, Syed S, Feltquate D (2008) A phase I study of brivanib alaninate (BMS-582664), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full dose cetuximab (BC) in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy. J Clin Oncol 26(May suppl). Abstract 4111","DOI":"10.1200\/jco.2008.26.15_suppl.4111"},{"key":"1603_CR26","doi-asserted-by":"crossref","unstructured":"Mekhail T, Masson E, Fischer B, Gong J, Iyer R, Gan J, Pursley J, Patricia D, Williams D, Ganapathi R (2010) Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. Drug Metab Dispos (29 Jul, Epub ahead of print). doi: 10.1124\/dmd.110.033951","DOI":"10.1124\/dmd.110.033951"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1603-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1603-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1603-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,9]],"date-time":"2019-06-09T12:32:18Z","timestamp":1560083538000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1603-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,3]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1603-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,3]]}}}